Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766)
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Demonstrating intracellular protein target engagement is an essential step in the development and progression of new chemical probes and potential small molecule therapeutics. However, this can be particularly challenging for poorly studied and noncatalytic proteins, as robust proximal biomarkers are rarely known. To confirm that our recently discovered chemical probe 1 (CCT251236) binds the putative transcription factor regulator pirin in living cells, we developed a heterobifunctional protein degradation probe. Focusing on linker design and physicochemical properties, we generated a highly active probe 16 (CCT367766) in only three iterations, validating our efficient strategy for degradation probe design against nonvalidated protein targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Activity-Based Protein Profiling: From Enzyme Chemistry to Proteomic Chemistry
Cravatt, B. F., Wright, A. T., & Kozarich, J. W. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.101304.124125 · Cited by 1,270
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Tracking cancer drugs in living cells by thermal profiling of the proteome
Savitski, M. M., Reinhard, F. B. M., Franken, H., Werner, T., Savitski, M. F., Eberhard, D., Molina, D. M., Jafari, R., Dovega, R. B., Klaeger, S., et al. (2014) · Science · doi:10.1126/science.1255784 · Cited by 1,187
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056
How does multiple testing correction work?
Noble, W. S. (2009) · Nature Biotechnology · doi:10.1038/nbt1209-1135 · Cited by 772
Molecular architecture and assembly of the DDB1–CUL4A ubiquitin ligase machinery
Angers, S., Li, T., Yi, X., MacCoss, M. J., Moon, R. T., & Zheng, N. (2006) · Nature · doi:10.1038/nature05175 · Cited by 674
Modular PROTAC design for the degradation of oncogenic BCR-ABL
Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618
A Comprehensive Mathematical Model for Three-Body Binding Equilibria
Douglass, E. F., Miller, C. J., Sparer, G., Shapiro, H., & Spiegel, D. A. (2013) · Journal of the American Chemical Society · doi:10.1021/ja311795d · Cited by 472
DCAFs, the Missing Link of the CUL4-DDB1 Ubiquitin Ligase
Lee, J., & Zhou, P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.001 · Cited by 460
A Perspective on the Kinetics of Covalent and Irreversible Inhibition
Strelow, J. M. (2017) · SLAS Discovery · doi:10.1177/1087057116671509 · Cited by 392
How Big Is Too Big for Cell Permeability?
Matsson, P., & Kihlberg, J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00237 · Cited by 303
Ohoka, N., Okuhira, K., Ito, M., Nagai, K., Shibata, N., Hattori, T., Ujikawa, O., Shimokawa, K., Sano, O., Koyama, R., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.768853 · Cited by 240
Impact of linker length on the activity of PROTACs
Cyrus, K., Wehenkel, M., Choi, E.-Y., Han, H.-J., Lee, H., Swanson, H., & Kim, K.-B. (2010) · Molecular BioSystems · doi:10.1039/c0mb00074d · Cited by 232
Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation
Ottis, P., Toure, M., Cromm, P. M., Ko, E., Gustafson, J. L., & Crews, C. M. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00485 · Cited by 176
Quantitating drug-target engagement in single cells in vitro and in vivo
Dubach, J. M., Kim, E., Yang, K., Cuccarese, M., Giedt, R. J., Meimetis, L. G., Vinegoni, C., & Weissleder, R. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2248 · Cited by 87
Research works printed but not linked: 50
- Swinney, 2004, Biochemical mechanisms of drug action: What does it take for success?, Nat. Rev. Drug Discovery, 3, 801, 10.1038/nrd1500 · DOI · Paper page
- Schürmann, 2016, Small-molecule target engagement in cells, Cell Chem. Biol., 23, 435, 10.1016/j.chembiol.2016.03.008 · DOI
- Simon, 2013, Determining target engagement in living systems, Nat. Chem. Biol., 9, 200, 10.1038/nchembio.1211 · DOI · Paper page
- Durham, 2015, Target engagement in lead generation, Bioorg. Med. Chem. Lett., 25, 998, 10.1016/j.bmcl.2014.12.076 · DOI · Paper page
- Sun, 2012, Monitoring protein interactions in living cells with fluorescence lifetime imaging microscopy, Methods Enzymol., 504, 371, 10.1016/B978-0-12-391857-4.00019-7 · DOI
- Robers, 2015, Target engagement and drug residence time can be observed in living cells with BRET, Nat. Commun., 6, 10091, 10.1038/ncomms10091 · DOI · Paper page
- Franken, 2015, Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry, Nat. Protoc., 10, 1567, 10.1038/nprot.2015.101 · DOI · Paper page
- Huber, 2015, Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling, Nat. Methods, 12, 1055, 10.1038/nmeth.3590 · DOI · Paper page
- Mateus, 2017, Thermal proteome profiling: unbiased assessment of protein state through heat-induced stability changes, Proteome Sci., 15, 13, 10.1186/s12953-017-0122-4 · DOI · Paper page
- Lanning, 2014, A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors, Nat. Chem. Biol., 10, 760, 10.1038/nchembio.1582 · DOI · Paper page
- Cheeseman, 2017, Discovery of a chemical probe bisamide (CCT251236): an orally bioavailable efficacious pirin ligand from a heat shock transcription factor 1 (HSF1) phenotypic screen, J. Med. Chem., 60, 180, 10.1021/acs.jmedchem.6b01055 · DOI
- Liu, 2013, Pirin is an iron-dependent redox regulator of NF-κB, Proc. Natl. Acad. Sci. U. S. A., 110, 9722, 10.1073/pnas.1221743110 · DOI · Paper page
- Dunwell, 2004, Cupins: the most functionally diverse protein superfamily?, Phytochemistry, 65, 7, 10.1016/j.phytochem.2003.08.016 · DOI · Paper page
- Komai, 2015, Pirin regulates epithelial to mesenchymal transition independently of BCL3-SLUG signaling, FEBS Lett., 589, 738, 10.1016/j.febslet.2015.01.040 · DOI
- Ohoka, 2016, Protein knockdown technology: Application of ubiquitin ligase to cancer therapy, Curr. Cancer Drug Targets, 16, 136, 10.2174/1568009616666151112122502 · DOI · Paper page
- Collins, 2017, Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway, Biochem. J., 474, 1127, 10.1042/BCJ20160762 · DOI · Paper page
- Toure, 2016, Small-molecule PROTACS: New approaches to protein degradation, Angew. Chem., Int. Ed., 55, 1966, 10.1002/anie.201507978 · DOI · Paper page
- Lai, 2017, Induced protein degradation: An emerging drug discovery paradigm, Nat. Rev. Drug Discovery, 16, 101, 10.1038/nrd.2016.211 · DOI · Paper page
- Galdeano, 2014, Structure guided design and optimization of small molecules targeting the protein-protein interaction between the von hippel-lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities, J. Med. Chem., 57, 8657, 10.1021/jm5011258 · DOI · Paper page
- Demizu, 2016, Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand, Bioorg. Med. Chem. Lett., 26, 4865, 10.1016/j.bmcl.2016.09.041 · DOI
- Petzold, 2016, Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase, Nature, 532, 127, 10.1038/nature16979 · DOI · Paper page
- Crew, 2017, Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1, J. Med. Chem., 10.1021/acs.jmedchem.7b00635 · DOI · Paper page
- Zhou, 2017, Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression, J. Med. Chem., 10.1021/acs.jmedchem.6b01816 · DOI · Paper page
- Robb, 2017, Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC), Chem. Commun., 53, 7577, 10.1039/C7CC03879H · DOI · Paper page
- Ruchelman, 2013, Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity, Bioorg. Med. Chem. Lett., 23, 360, 10.1016/j.bmcl.2012.10.071 · DOI
- Lohbeck, 2016, Practical synthesis of a phthalimide-based cereblon ligand to enable PROTAC development, Bioorg. Med. Chem. Lett., 26, 5260, 10.1016/j.bmcl.2016.09.048 · DOI
- Georgsson, 2003, Rapid palladium-catalyzed synthesis of esters from aryl halides utilizing Mo(CO)6 as a solid carbon monoxide source, J. Comb. Chem., 5, 350, 10.1021/cc0201086 · doi:10.1021/cc0201086
- Georgsson, 2005, Angiotensin II pseudopeptides containing 1,3,5-trisubstituted benzene scaffolds with high AT2 receptor affinity, J. Med. Chem., 48, 6620, 10.1021/jm050280z · DOI
- Chan, 2017, Impact of target warhead and linkage vector on inducing protein degradation: Comparison of bromodomain and extra-terminal (BET) degraders derived from triazolodiazepine (JQ1) and tetrahydroquinoline (I-BET726) BET inhibitor scaffolds, J. Med. Chem., 10.1021/acs.jmedchem.6b01912 · DOI · Paper page
- Huang, 2003, Fluorescence polarization competition assay: The range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand, J. Biomol. Screening, 8, 34, 10.1177/1087057102239666 · DOI · Paper page
- Munson, 1988, An exact correction to the ″Cheng-Prusoff″ correction, J. Recept. Res., 8, 533, 10.3109/10799898809049010 · DOI · Paper page
- Erales, 2014, Ubiquitin-independent proteasomal degradation, Biochim. Biophys. Acta, Mol. Cell Res., 1843, 216, 10.1016/j.bbamcr.2013.05.008 · DOI · Paper page
- Mateus, 2017, Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery, Proc. Natl. Acad. Sci. U. S. A., 114, E6231, 10.1073/pnas.1701848114 · DOI · Paper page
- Pye, 2017, Nonclassical size dependence of permeation defines bounds for passive adsorption of large drug molecules, J. Med. Chem., 60, 1665, 10.1021/acs.jmedchem.6b01483 · DOI · Paper page
- Hann, 2012, Finding the sweet spot: The role of nature and nurture in medicinal chemistry, Nat. Rev. Drug Discovery, 11, 355, 10.1038/nrd3701 · DOI · Paper page
- Palm, 1998, Evaluation of dynamic polar molecular surface area as predictor of drug absorption: Comparison with other computational and experimental predictors, J. Med. Chem., 41, 5382, 10.1021/jm980313t · DOI · Paper page
- Gillis, 2015, Applications of fluorine in medicinal chemistry, J. Med. Chem., 58, 8315, 10.1021/acs.jmedchem.5b00258 · DOI · Paper page
- George, 2013, Synthesis of iodopyridone, Tetrahedron, 69, 8209, 10.1016/j.tet.2013.07.033 · doi:10.1016/j.tet.2013.07.033
- Lepper, 2006, Thalidomide metabolism and hydrolysis: mechanisms and implications, Curr. Drug Metab., 7, 677, 10.2174/138920006778017777 · DOI · Paper page
- Reist, 1998, Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites, Chem. Res. Toxicol., 11, 1521, 10.1021/tx9801817 · DOI · Paper page
- Goodwin, 2001, Physicochemical determinants of passive membrane permeability: Role of solute hydrogen-bonding potential and volume, J. Med. Chem., 44, 3721, 10.1021/jm010253i · DOI
- Evans, 2017, Targeting secondary protein complexes in drug discovery: studying the druggability and chemical biology of the HSP70/BAG1 complex, Chem. Commun., 53, 5167, 10.1039/C7CC01376K · DOI
- Youdim, 2003, In vitro trans-monolayer permeability calculations: Often forgotten assumptions, Drug Discovery Today, 8, 997, 10.1016/S1359-6446(03)02873-3 · DOI · Paper page
- Filipe, 2014, Beyond Overton’s rule: Quantitative modeling of passive permeation through tight cell monolayers, Mol. Pharmaceutics, 11, 3696, 10.1021/mp500437e · DOI
- Owen, 2014, Colloidal drug formulations can explain “bell-shaped” concentration-response curves, ACS Chem. Biol., 9, 777, 10.1021/cb4007584 · DOI
- Kisselev, 2001, Proteasome inhibitors: From research tools to drug candidates, Chem. Biol., 8, 739, 10.1016/S1074-5521(01)00056-4 · DOI · Paper page
- Diz, 2011, Multiple hypothesis testing in proteomics: A strategy for experimental work, Mol. Cell. Proteomics, 10, M110.004374, 10.1074/mcp.M110.004374 · DOI · Paper page
- Thorarensen, 2014, ATP-mediated kinome selectivity: The missing link in understanding the contribution of individual JAK kinase isoforms to cellular signaling, ACS Chem. Biol., 9, 1552, 10.1021/cb5002125 · DOI
- Smyth, 2009, Measuring and interpreting the selectivity of protein kinase inhibitors, J. Chem. Biol., 2, 131, 10.1007/s12154-009-0023-9 · DOI · Paper page
- Knight, 2005, Features of selective kinase inhibitors, Chem. Biol., 12, 621, 10.1016/j.chembiol.2005.04.011 · DOI · Paper page
Cited by
PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future
Pettersson, M., & Crews, C. M. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.01.002 · Cited by 800
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 613
Edmondson, S. D., Yang, B., & Fallan, C. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.04.030 · Cited by 422
Current strategies for the design of PROTAC linkers: a critical review
Troup, R. I., Fallan, C., & Baud, M. G. J. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00018 · Cited by 424
“[126], developed pirin-targeting protein degradation probe (PDP) CCT367766 (84), having previously reported a high affinity benzodioxine based ligand for pirin.”
BackgroundProteolysis-targeting chimeras (PROTACs) in cancer therapy
Li, X., Pu, W., Zheng, Q., Ai, M., Chen, S., & Peng, Y. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01434-3 · Cited by 337
Metadata
- Authors
- Chessum, N. E. A., Sharp, S. Y., Caldwell, J. J., Pasqua, A. E., Wilding, B., Colombano, G., Collins, I., Ozer, B., Richards, M., Rowlands, M., Stubbs, M., Burke, R., McAndrew, P. C., Clarke, P. A., Workman, P., Cheeseman, M. D., & Jones, K.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-01-05
- Volume
- 61
- Issue
- 3
- Pages
- 918-933
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2774715474
- Cited by
- 91
- References
- 20
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Cancer Research UK (C309/A11566, C309/A8274)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.